KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 7028 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. PMID 35032434 · Lancet Haematol · 2022-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. PMID 35030335 · Lancet Oncol · 2022-Feb 命中用户提供的消化道肿瘤阳性参考集。
H L S B
旧组与严格 v3 交集 eligiblepositive_reference needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial. PMID 35019221 · J Dig Dis · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Benefits of immunonutrition in patients with head and neck cancer receiving chemoradiation: A phase II randomized, double-blind study. PMID 35007812 · Clin Nutr · 2022-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy. PMID 34979212 · Radiother Oncol · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia. PMID 34973513 · ESMO Open · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. PMID 34971660 · Radiother Oncol · 2022-Feb While the record references Phase III randomized trials with a time-to-event endpoint (PFS), the provided text is not the original primary result report of a trial with a drug-containing intervention. It is an analysis and validation paper using trial data. The drug intervention criterion is not explicitly established in the abstract, making the record ineligible.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical application of protein-enhanced diet using mealworms in patients undergoing hepato-pancreato-biliary surgery. PMID 34965499 · Nutrition · 2022-Feb The study is a Phase III randomized trial in a surgical oncology population, but it lacks a time-to-event efficacy endpoint. The primary endpoint is a change in body composition/nutritional status, and secondary endpoints are immune cell activity. The intervention is a protein-enhanced diet, not a drug intervention for cancer treatment.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial. PMID 34957550 · Epilepsia · 2022-Feb 未发现恶性肿瘤人群证据。
H L S B
旧组与严格 v3 交集 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. PMID 34953531 · Lancet Diabetes Endocrinol · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. PMID 34953042 · Cancer Med · 2022-Feb This is a re-analysis of a Phase III RCT in AML with a drug intervention, but it does not report a standard time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR as the primary/key secondary analysis. The study evaluates a composite endpoint (current leukemia-free survival) using multi-state models, which is a methodological focus rather than a standard efficacy endpoint for inclusion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. PMID 34952708 · Gynecol Oncol · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Consistently High Agreement Between Independent Raters of Niemann-Pick Type C1 Clinical Severity Scale in Phase 2/3 Trial. PMID 34952292 · Pediatr Neurol · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease. PMID 34937388 · Arterioscler Thromb Vasc Biol · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. PMID 34911706 · Ann Rheum Dis · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. PMID 34906376 · Gynecol Oncol · 2022-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. PMID 34903380 · Gynecol Oncol · 2022-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. PMID 34860318 · Breast Cancer Res Treat · 2022-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study. PMID 34857397 · Gynecol Oncol · 2022-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients. PMID 34801738 · Int J Infect Dis · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. PMID 34800364 · Lancet Respir Med · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. PMID 34798039 · Lancet Gastroenterol Hepatol · 2022-Feb The study is a Phase III randomized controlled trial of a drug, but it is not in oncology; it is for ulcerative colitis. Furthermore, the primary efficacy endpoint is clinical remission at fixed time points, not a time-to-event outcome such as OS, PFS, DFS, etc. There is no mention of Kaplan-Meier curves or hazard ratios for time-to-event data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. PMID 34798038 · Lancet Gastroenterol Hepatol · 2022-Feb This is a Phase 3 randomized trial of a drug intervention (etrolizumab vs. infliximab) for ulcerative colitis, which is a non-oncology inflammatory bowel disease. The primary efficacy endpoint is a composite clinical response/remission endpoint (binary proportion at week 54), not a time-to-event efficacy endpoint such as OS, PFS, DFS, or TTP. Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. PMID 34775146 · Transplant Cell Ther · 2022-Feb The record describes a Phase III randomized trial with time-to-event efficacy endpoints in human oncology. However, the drug intervention is not explicitly established in the provided abstract. The intervention appears to be transplantation procedures (umbilical cord blood or HLA-haploidentical bone marrow/peripheral blood), which are procedural, not necessarily drug-based. The eligibility criteria require a drug-containing intervention, which cannot be confirmed from the metadata. Therefore, eligibility is indeterminate.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. PMID 34774185 · Lancet Respir Med · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials. PMID 34773130 · Rheumatol Int · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial. PMID 34728786 · Bone Marrow Transplant · 2022-Feb The study is a randomized Phase III oncology trial with a drug intervention (conditioning chemotherapy), but the primary efficacy endpoint is a continuous outcome measure (Oral Mucositis Assessment Scale score), not a time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) reported with Kaplan-Meier or hazard ratios. Therefore, it does not meet the cohort's requirement for a time-to-event primary/key secondary endpoint.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. PMID 34686445 · Clin Lymphoma Myeloma Leuk · 2022-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). PMID 34676663 · BJOG · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients. PMID 34674258 · Clin Pharmacol Ther · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. PMID 34648948 · J Thorac Oncol · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. PMID 34647404 · Diabetes Obes Metab · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. PMID 34634163 · J Eur Acad Dermatol Venereol · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. PMID 34616010 · Br J Cancer · 2022-Feb The study is an original report of Phase III randomized trials with a drug intervention (bevacizumab) in oncology patients, but it is a pharmacogenomic toxicity analysis (hypertension and proteinuria) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children. PMID 34606114 · Acta Paediatr · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. PMID 34560137 · Kidney Int · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. PMID 34534511 · Lancet Infect Dis · 2022-Feb The record describes a randomized phase 3 trial of remdesivir for COVID-19, not a human malignant-neoplasm (oncology) study. Furthermore, the primary efficacy endpoint is a categorical clinical status score (WHO ordinal scale), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. PMID 34526397 · J Rheumatol · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. PMID 34524700 · J Clin Pharmacol · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. PMID 34431071 · Clin Pharmacokinet · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. PMID 34420037 · Prostate Cancer Prostatic Dis · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized trial of two maintenance doses of vitamin D in children with chronic kidney disease. PMID 34392411 · Pediatr Nephrol · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model. PMID 34379314 · Clin Pharmacokinet · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation. PMID 34363198 · Reprod Sci · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER. PMID 33971353 · Ophthalmol Retina · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sustained-release isosorbide mononitrate as adjuvant treatment in isolated systolic hypertension in the elderly. PMID 33850272 · J Hum Hypertens · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis. PMID 33724104 · Int J Stroke · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda. PMID 33542153 · Sex Transm Infect · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. PMID 33279779 · Clin Gastroenterol Hepatol · 2022-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab. PMID 32937016 · Arthritis Care Res (Hoboken) · 2022-Feb 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -